Form 4: Richard P. Blumberg Reports Acquisition of Guided Therapeutics Inc. Shares Through Dividend Payments

Richard P. Blumberg, a director and 10% owner of Guided Therapeutics Inc., reports acquiring additional shares through the conversion of accrued dividends from Series F and F-2 preferred stock.

Summary

• On March 26, 2024, Richard P. Blumberg acquired 114,912 shares of common stock due to accrued dividends on Series F preferred stock.
• These shares were converted at a price of $0.1361 per share.
• Additionally, Blumberg acquired 38,893 shares of common stock from accrued dividends on Series F-2 preferred stock, also at a conversion price of $0.1361.
• Following these transactions, Blumberg directly owns 6,119,162 shares of Guided Therapeutics Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock acquisitions through dividend payments. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.

Industry Context

This filing reflects insider activity related to dividend payments and stock conversion, which is a common practice for companies with preferred stock issuances. It provides insight into the holdings of a significant shareholder.

Stakeholder Impact

• The transaction increases the insider ownership stake, which could be viewed positively by some shareholders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Richard P. Blumberg, Guided Therapeutics Inc., GTHP, Dividend, Series F Preferred Stock, Series F-2 Preferred Stock, Conversion